ALS Investment Fund
VC Fund
Amsterdam, The Netherlands
ALS Investment Fund is a VC fund in Amsterdam focused on Biotechnology and Health Care. The ALS Investment Fund supports and finances biotech companies
- Total investments:
- 7
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries ALS Investment Fund invests in
Stages ALS Investment Fund invests in
Countries ALS Investment Fund invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Felix von Coerper
|
|||
Investment Focus
Industry
- Biotechnology 7 (100%)
- Health Care 5 (71%)
- Life Science 3 (43%)
- Pharmaceutical 3 (43%)
- Genetics 2 (29%)
Stage
- Series A 3 (43%)
- Series B 2 (29%)
- Series C 1 (14%)
- Funding Round 1 (14%)
Country
- United States 4 (57%)
- Israel 1 (14%)
- Denmark 1 (14%)
- The Netherlands 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Felix von Coerper
Managing Partner
|
Managing Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
VectorY
|
VectorY is a fully integrated gene therapy company specializing in the development of novel therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a particular emphasis on muscle diseases. It combines the therapeutic potential of antibodies and gene therapy to create long-term therapeutic solutions for large diseaseareas with significant unmet medical need.VectorY was founded in the Amsterdam Science Park in August 2020. | $138M / Series A / Nov 13, 2023 | |
Verge Genomics
|
Verge Genomics transforms drug discovery with artificial intelligence. Verge was founded by a unique combination of the field's top machine learning experts and seasoned neuroscience drug developers. Together, they share the vision that exponential advances in computational genomics combined with new insights into neuroscience has created abreakthrough opportunity to discover drugs that dramatically improve the lives of patients suffering from neurodegenerative disease. | $98M / Series B / Dec 16, 2021 | |
Bloom Science
|
Bloom Science is a platform biotechnology company discovering and developing genetically optimized microbes with potential to treat millions of patients with pharmacoresistant or non-addressed diseases. | $12M / Series A / Dec 09, 2021 | |
Prilenia
|
Prilenia is a clinical-stage biotech company that develops novel treatments for neurodegenerative and neurodevelopmental disorders. Its lead asset is Pridopidine, a n oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children.The company wasfounded in 2018 and is based in Israel, the Netherlands, and Boston. | $43M / Series B / Nov 03, 2021 | |
Apic Bio
|
Apic Bio is a gene therapy company that develops treatment options for rare, undertreated neurological and liver diseases. The company is advancing several novel gene therapies to treat Alpha-1 Antitrypsin Deficiency (Alpha-1), genetic Amyotrophic Lateral Sclerosis (ALS), and other CNS diseases. | $42.3M / Series A / Jan 07, 2019 | |
Emulate
|
Emulate is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health. | $36M / Series C / Jun 18, 2018 | |
Orphazyme
|
Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse).Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA. | $15.4M / Mar 08, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does ALS Investment Fund invest in?
ALS Investment Fund invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact ALS Investment Fund?
Public channels for ALS Investment Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ALS Investment Fund?
The team at ALS Investment Fund includes Felix von Coerper (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
